Exact Sciences

EXAS

Last Price
03/23/26, 09:30 AM
 EDT
$
104.91
(
0.0
%)
(
+
0.0
%)
Margin of Safety
+
0.1
%
Modeled Fair Value
$
105.00
Modeled Fair Value
$12.435 billion
Allocation Group
Current Compounder
Allocation Tier
Coming soon!

Investment Thesis

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
An icon graphic of Gouldy the Finch.
#protectYourAssets

Solt DB will launch asset deep dives for all companies in the coverage ecosystem by the end of 2026. These will seamlessly integrate into company-specific financial models, allowing members to determine a company's fair value when specific assets are included or excluded.

Want me to prioritize a specific company or asset? Let me know on Discord or through the contact page.

Last Refined

February 13, 2026
The current model INCLUDES the following assets and assumptions:
The current model is based on operating metrics, including:
  • The model now reflects the acquisition price of $105 per share. The 2026 model basis is presented below, which has a fair value of $64.40 per share.
  • Full-year 2026 revenue of $3.598 billion, representing year-over-year growth of 13.9%.
  • Screening segment revenue of $2.851 billion, representing year-over-year growth of 15.7%.
  • Precision Oncology segment revenue of $746 million, representing year-over-year growth of 7.5%.
  • Operating income of $349 million.
  • Net income of $329 million to $369 million, or earnings per share (EPS) of $1.70 to $1.91.
  • Excludes blood-based screening tools.
The current model EXCLUDES the following assets:

SEC Filings